On Tuesday, Merck & Co Inc (NYSE:MRK) reported second-quarter sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%. Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15. The pharmaceutical unit booked $14.41 billion in revenue, up 7% year over year. Growth in oncology, cardiovascular, and vaccines, partially offset by declines in diabetes and virology, drove the growth. Also Read: Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits. Merck’s blockbuster cancer immunotherapy Keytruda generated $7.27 billion in revenue during the quarter, up ...